

**INVESTIGATION OF THE ASSOCIATIONS OF SMOKING-  
RELATED DNA DAMAGES WITH BIOMARKERS IN A  
HUMAN LUNG CANCER POPULATION**

**PhD theses**

**Lívia Anna**

**Department of Public Health Medicine  
Medical School  
University of Pécs**

**Supervisor: Dr. Bernadette Schoket, PhD  
Program leader: Prof. Dr. med. habil. István Ember, DSc**

**2012**

## Introduction


Lung cancer rate in Hungary is one of the highest in the world among men and also very high among women, for reasons not clearly understood yet. The primary risk factor for lung cancer is smoking. In Hungary, cigarette consumption is high, but not substantially different from the cigarette consumption of other much-smoking countries. The risks associated with other potential etiological factors, such as asbestos and radon exposure, are not known to be different in Hungary from those in many other European countries. Therefore, the complex molecular mechanisms of the disease should be further explored in order to reveal the reasons for the very high lung cancer rate in Hungary.

Tobacco smoke contains more than 4000 constituents including polycyclic aromatic hydrocarbons (PAHs), heterocyclic amines, N-nitrosamines and aldehydes, many of which are genotoxic. Some carcinogenic agents damage the DNA directly, but the majority of the carcinogenic agents undergo metabolic activation before they become biologically active. The biological markers, or briefly biomarkers, used in molecular epidemiology, are biological materials, components or processes that can be detected and measured in the human body; they reflect processes and changes in the organism, may influence the onset or outcome of a disease, or may indicate the risk of a disease. The new knowledge gained from biomarker research may facilitate the reduction of adverse health effects of human environmental exposure and the occurrence of certain diseases. The main groups of biomarkers that characterise the multi-step process of carcinogenesis are the exposure markers, such as DNA adducts, the effect markers, such as gene mutations, and susceptibility markers that may influence the whole process.

The complex molecular mechanisms of lung cancer can be investigated and characterised by the different types of biomarkers and by the associations among them. In my doctoral dissertation I have investigated the associations among bulky DNA adducts and O<sup>4</sup>-ethylthymidine that are biomarkers of exposure, the *TP53* gene mutation spectra as a biomarker of effect, and smoking exposure as the main environmental risk factor of lung cancer.

## Aims of the research

The aim of my multi-endpoint molecular epidemiological research was to further explore the molecular background of lung carcinogenesis in Hungarian lung cancer patients with the application of exposure and effect biomarkers. The research was based on the previous studies of our research team on smoking-related bulky DNA adduct formation. The scheme here below shows the main stages of the carcinogenic pathway initiated by cigarette smoke exposure, and the circles indicate the exposure and the biomarkers investigated in the project.



The scheme of the carcinogenic pathway initiated by cigarette smoke

I extended my investigations in the frame of international collaborative projects to a hardly-known type of DNA damage, O<sup>4</sup>-ethylthymidine (O<sup>4</sup>-etT) to explore whether it is suitable for use as biomarker of smoking exposure. Thus, a major aim of my research was to explore new exposure biomarkers in target tissue, here, specifically in human lung tissue. I analysed separately and in correlation the dose-dependency and the elimination of the two different types of DNA adducts in order to explore possible links between their formation and elimination pathways. For the first time, I investigated the *TP53* gene mutations in association with the smoking status and tumour histology in a Hungarian lung cancer population in order to compare the Hungarian characteristics with international statistics. The international novelty of my research is that this is the first human study in which the associations between

smoking-related bulky DNA adducts as primary DNA damage, and specific *TP53* tumour suppressor gene mutations as a possible consequence have been investigated for possible causal relationship that had been suggested by previous experimental model studies.

## **Materials and methods**

### Study population

Lung tissue samples derived from 104 primary lung cancer patients who underwent lung resection in the Department of Thoracic Surgery of the Korányi National Institute of Tuberculosis and Pulmonology (Budapest, Hungary). Macroscopically normal and tumour tissues samples were taken from the resected lobes, and DNA was isolated from the tissues. The study population comprised 37 squamous cell carcinoma and 67 adenocarcinoma cases. 60% of the cases were males (n=62) and 40% (n=42) females.

### DNA isolation

DNA was isolated from the lung tissues samples by using the phenol – chloroform – iso-amyl alcohol extraction procedure.

### Determination of bulky DNA adducts by <sup>32</sup>P-postlabelling

Bulky DNA adducts were determined in the genomic DNA from the non-tumorous (n=104) and tumour tissue samples (n=57) by using the <sup>32</sup>P-postlabelling method combined with nuclease P1 adduct enrichment. The radio-labelled DNA adducts were separated with multi-directional thin-layer chromatography. Detection of the adduct patterns and measurement of radioactivity were done by electronic autoradiography.

### O<sup>4</sup>-ethylthymidine determination with <sup>32</sup>P-HPLC method

O<sup>4</sup>-etT levels were determined from the macroscopically normal lung tissue samples (n=64) with a modified immunoenriched <sup>32</sup>P-postlabelling method, followed by separation on reverse-phase high-performance liquid chromatography (HPLC) with gradient elution, and online detection of radioactivity.

### *TP53* mutation detection

*TP53* mutations were analysed from the tumour tissues (n=104) in exons 5-9 and 11. The *TP53* gene sequences were amplified from the DNA samples by polymerase chain reaction (PCR). Denaturant gradient gel electrophoresis (DGGE) and automated capillary electrophoresis single strand conformation polymorphism (CE-SSCP) were applied to screen for *TP53* mutations. The mutations were determined by direct sequencing.

### Statistical analyses

The statistical analyses were performed with GraphPad Prism 4.0 software, using Fisher's exact test and Mann-Whitney U-test, and Spearman correlation test. Two-sided P values are given, and a difference was considered statistically significant at  $P \leq 0.05$ .

## Summary of the results

The aim of my PhD research was to further explore the associations among smoking status, two different DNA adduct types, the O<sup>4</sup>-etT and bulky DNA adduct, the *TP53* tumour suppressor gene mutations and lung cancer in a molecular epidemiological study in a Hungarian lung cancer study population.

The levels of O<sup>4</sup>-etT and bulky DNA adducts were significantly higher in the combined group of subjects who smoked until surgery or gave up smoking at most one year before surgery than in the combined group of those subjects who gave up smoking more than one year before the surgery or never smoked. O<sup>4</sup>-etT appeared to be a highly persistent DNA damage. There was no statistically significant correlation between the individual levels of O<sup>4</sup>-etT and of bulky DNA adducts.

The *TP53* mutation frequency and the variety of mutation types were higher in the present study population as compared to the IARC database. 45% of the samples carried *TP53* mutation. The mutation frequency was significantly higher in squamous cell carcinoma than in adenocarcinoma, and in the cases with more than 20 years of smoking history. The most common mutations were G→A (19%), G→T (19%) and G→C (16%) base changes. The mutation pattern was influenced by the smoking status. G→T transversion was detected

exclusively in smokers, and most carriers of the G→T transversions had also high level of bulky DNA adducts.

My results confirm that O<sup>4</sup>-etT level is increased by smoking in the lung. O<sup>4</sup>-etT is persistent in human lung, and the activation and elimination pathways of O<sup>4</sup>-etT and bulky DNA adducts are not closely linked. I consider O<sup>4</sup>-etT a suitable biomarker of smoking exposure for comparison of exposure groups in molecular epidemiological studies.

For the first time at international level, I demonstrated strong association between G→T mutation of *TP53* and high level of bulky DNA adducts in a human study, which is a significant scientific progress from the *in vitro* studies in the exploration of the causal relationship between a carcinogen-DNA adduct and a gene mutation.

### **Highlighted novel scientific findings**

1. My results indicate that the main source of O<sup>4</sup>-etT formation in human lung is smoking. O<sup>4</sup>-etT is applicable in molecular epidemiological studies as a biomarker of smoking exposure.
2. My results demonstrate the long persistence of O<sup>4</sup>-etT in human lung for several years after quitting smoking, contrary to bulky DNA adducts.
3. Although the major source of O<sup>4</sup>-etT and bulky DNA adduct formation in lung is smoking, their metabolic pathways and DNA repair processes are probably not closely linked.
4. Higher *TP53* mutation frequency was found in the Hungarian lung cancer study population than in several Caucasian, South-American and Asian lung cancer populations, and its mutation frequency is among the highest ones published in the literature.
5. I found associations between *TP53* mutation frequency and gender, smoking dose, duration of smoking, and the histological type of tumour.
6. *TP53* mutation spectra were similar in never-smokers and in those former smokers who gave up smoking more than a year before surgery.

7. For the first time at international level, I demonstrated relationship between the high level of bulky DNA adducts and the smoking exposure-specific G→T transversion in human lung cancer.

## Publications

### *Publications related to the PhD dissertation in scientific journals and book*

Anna,L., Kovács,K., Győrffy,E., Schoket,B., Nair,J. (2011) Smoking-related O<sup>4</sup>-ethylthymidine formation in human lung tissue and comparisons with bulky DNA adducts, *Mutagenesis*, 26, 523-527. **Impact factor: 3.98**

Anna,L., Holmila,R., Kovács,K., Győrffy,E., Győri,Z., Segesdi,J., Minárovits,J., Soltész,I., Kostic,S., Csekeő,A., Husgafvel-Pursiainen,K., Schoket,B. (2010) *TP53* tumorszupresszor génmutáció vizsgálatok magyar tüdőrákos betegcsoportban. *Egészségtudomány*, 54, 57-69.

Anna,L., Holmila,R., Kovács,K., Győrffy,E., Győri,Z., Segesdi,J., Minárovits,J., Soltész,I., Kostic,S., Csekeő,A., Husgafvel-Pursiainen,K., Schoket,B. (2009) Relationship between TP53 tumour suppressor gene mutations and smoking related bulky DNA adducts in a lung cancer study population from Hungary. *Mutagenesis*, 24, 475-480. **Impact factor: 3.54**

Győrffy,E., Anna,L., Győri,Z., Segesdi,J., Minárovits,J., Soltész,I., Kostic,S., Csekeő,A., Poirier,M.C., Schoket,B. (2004) DNA adducts in tumour, normal peripheral lung and bronchus, and peripheral blood lymphocytes from smoking and non-smoking lung cancer patients: correlations between tissues and detection by <sup>32</sup>P-postlabelling and immunoassay. *Carcinogenesis*, 25, 1201–1209. **Impact factor: 5.40**

Győrffy,E., Anna,L., Kovács,K., Rudnai P., Schoket,B. (2008) Correlation between biomarkers of human exposure to genotoxins with focus on carcinogen–DNA adducts. *Mutagenesis*, 23, 1–18. **Impact factor: 3.16**

Gallo,V., Khan,A., Gonzales,C., Phillips,D.H., Schoket,B., Győrffy,E., Anna,L., Kovács,K., Møller,P., Loft,S., Kyrtopoulos,S., Matullo,G., Vineis,P. (2008) Validation of biomarkers for the study of environmental carcinogens: a review. *Biomarkers*, 13, 505-534. **Impact factor: 1.73**

Győrffy,E., Anna,L., Rudnai,P., Kovács,K., Schoket,B. (2006) Correlations among biomarkers. In: Farmer,P., Emeny,J.M. (eds.), *Biomarkers of carcinogen exposure and early effect*. ECNIS, Nofer Institute of Occupational Medicine, Lodz, Poland, pp. 143–159.

### ***Publications beyond the subject of the PhD dissertation in scientific journals and book***

Kovács,K., Anna,L., Rudnai,P., Schoket,B. (2011) Recovery of bulky DNA adducts by the regular and a modified <sup>32</sup>P-postlabelling assay; influence of the DNA-isolation method. *Mutat. Res.*, 721, 95–100. **Impact factor: 2.56**

Kovács,K., Győrffy,E. Anna,L., Schoket,B. (2006) Környezeti policiklusos aromás szénhidrogén expozíció biomonitorozása vizelet 1-hidroxipirén tartalmának meghatározásával – gyermekekre és felnőttekre vonatkozó szakirodalmi adatok összehasonlítása. *Egészségtudomány*, 50, 188–193.

Georgiadis,P., Kovács,K., Kaila,S., Makedonopoulou,P., Anna,L., Poirier,M.C., Knudsen,L.E., Schoket,B., Kyrtopoulos,S.A. (2012) Development and validation of a direct sandwich chemiluminescence immunoassay (SCIA) for measuring DNA adducts of benzo[a]pyrene and other polycyclic aromatic hydrocarbons. *Mutagenesis*. May 18. [Epub ahead of print] **Impact factor: 3.98**

Kovács,K., Győrffy,E., Anna,L., Schoket,B.: 1-Hydroxypyrene (2007) In: Vineis,P., V. Gallo,V. (eds.), *Epidemiological concepts of validation of biomarkers for the identification/quantification of environmental carcinogenic exposures*. ECNIS, The Nofer Institute of Occupational Medicine, Lodz, Poland, pp. 75–82.

### ***Abstracts in scientific journals***

Anna,L., Kovács,K., Lukács,V., Győrffy,E., Rudnai,P., Schoket,B.: Assessment of exposure to polycyclic aromatic hydrocarbons during pregnancy with bulky DNA adduct biomarker in European mother - child cohorts. *Mutagenesis* 26:5, 2011. **Impact factor: 3.983**

Kovács,K., Anna,L., Győrffy,E., Schoket,B.: The impact of pre-analytical processing of human tissue samples on the measurement of bulky DNA adducts by <sup>32</sup>P-postlabelling. *Mutagenesis*. 26:5, 2011. **Impact factor: 3.983**

Anna,L., Holmila,R., Kovács,K., Győrffy,E., Győri,Z., Segesdi,J., Minárovits,J., Soltész,I., Kostic,S., Csekeő,A., Husgafvel-Pursiainen,K., Schoket,B.: A *TP53* génmutáció és az aromás DNS-adduktszint közötti összefüggés tüdőrákos dohányzóknál. *Magyar Onkológia* 53:6, 2009.

Rudnai,P., Varró,M.J., Rudnai,T., Náray,M., Schoket,B., Anna,L., Győrffy,E., Kovács, K., Ürömi,J., Herczegh,T., Bodnár,J.: Associations between the children's blood lead level and their health status. *Epidemiology*, 20(6): S260, 2009. **Impact factor: 5.5**

Kovács,K., Győrffy,E. Anna,L., Schoket,B.: Urinary 1-hydroxypyrene as a biomarker of polycyclic aromatic hydrocarbon exposure in the general population and correlation between 1-hydroxypyrene and white blood cell DNA adducts - Results of our literature survey, *European J. Mol. Genetic Toxic.*; <http://www.swan.ac.uk/cget/ejgt1.htm>, 2006.

Anna,L., Győrffy,E., Győri,Z., Segesdi,J., Minárovits,J., Soltész,I., Kostič,Sz., Csekeő,A., Holmila,R., Husgafvel-Pursiainen,K., Schoket,B.: *TP53* Tumorsuppresszor gén vizsgálatok magyar tüdőrákos beteganyagban. Magyar Onkológia 49: 3, 2005.

Győrffy,E., Saarikoski,S., Holmila,R., Anna,L., Husgafvel-Pursiainen,K., Schoket,B., Rudnai,P.: A *CYP2S1* genetikai polimorfizmus mint potenciális tüdőrák rizikótényező magyar populációban. Magyar Onkológia 49: 27, 2005.

Győrffy,E., Saarikoski,S., Anna,L., Győri,Z., Segesdi,J., Minárovits,J., Soltész,I., Kostič,S., Csekeő,A., Husgafvel-Pursiainen,K., Schoket,B.: *CYP2S1* genetic polymorphism and smoking-related bulky carcinogen-DNA adducts in a Hungarian lung cancer population. Dis. Markers 20: 22, 2004. **Impact factor: 0.921**

Dám,A.M., Anna,L., Drahos,Á., Győrffy,E., Schoket,B.: In-vitro model for the investigation of combined genotoxic effect of polycyclic aromatic hydrocarbons and alpha particles in cell culture. Dis. Markers 20: 33, 2004. **Impact factor: 0.921**

Anna,L., Győrffy,E., Holmila,R., Győri,Z., Segesdi,J., Minárovits,J., Soltész,I., Kostič S., Csekeő,A., Husgafvel-Pursiainen,K., Schoket,B.: The relationship between Arg72Pro genetic polymorphism and gene mutations of *TP53* and smoking-related lung DNA adducts in a Hungarian lung cancer population. Dis. Markers 20: 23, 2004. **Impact factor: 0.921**

Anna,L., Győrffy,E., Győri,Z., Minárovits,J., Soltész,I., Kostič,Sz., Csekeő,A., Poirier,M.C., Holmila,R., Husgafvel-Pursiainen, K., Schoket,B.: *TP53* mutations and smoking-related DNA adducts in a Hungarian lung cancer population; Pharmacology and Toxicology; Volume 93: Suppl. I, 2003. **Impact factor: 1.271**

Anna,L., Győrffy,E., Győri,Z., Segesdi,J., Minárovits,J., Soltész,I., Kostič,S., Csekeő,A., Holmila,R., Husgafvel-Pursiainen,K., Schoket,B.: *TP53* mutációk hazai tüdőrákos beteganyagban, Magyar Onkológia. 47: 235, 2003.

***30 International and national conference participations as first author with poster and/or oral presentations.***

***51 International and national conference participations as co-author with poster and/or oral presentations.***

## Acknowledgements

I conducted my doctoral research as biologist co-worker in the National Institute of Environmental Health (NIEH), Budapest, Hungary. I wish to thank Dr. Gyula Dura, Director General of the Institute and Dr. Péter Rudnai, Head of the Division of Environmental Health Impact, and since 2008 the Head of the Department of Molecular Environmental Epidemiology for the generous support to make available the institute's technical and scientific means, and for supporting my preparation for the doctoral degree.

I express my special thanks to my supervisor, Dr. Bernadette Schoket, who had been the Head of the Department of Molecular Environmental Epidemiology and its predecessor Department of Applied Biochemistry until 2008, and who guided my doctoral research from the very beginning till the very end. The research has been based on her concepts, and the work was financially supported by the successful national and EU projects in which our research-team participated under her leadership. I specially thank her for the great scientific and personal support in preparation of the publications and the dissertation.

I thank Professor Dr. István Ember, Head of the Department of Public Health Medicine, Medical School, University of Pécs, for the devoted support during the doctoral process.

I conducted the O<sup>4</sup>-ethylthymidine measurements in the German Cancer Research Centre (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg, Germany, under the leadership of the late Dr. Jagadeesan Nair. I would like to pay honour to his memory for his scientific support.

I am grateful to Dr. Roger Godschalk (Maastricht University, Maastricht, The Netherlands) and Dr. Helmut Bartsch (Deutsches Krebsforschungszentrum, DKFZ, Heidelberg, Germany) for their precious scientific comments in preparation of the publication related to the O<sup>4</sup>-ethylthymidine study.

I wish to kindly thank Professor Dr. Kirsti Husgafvel-Pursiainen at the Finnish Institute of Occupational Health (FIOH, Helsinki, Finland), for the scientific leadership of the *TP53* mutation analyses and Dr. Reetta Holmila for the help in the *TP53* mutation analyses. I am grateful for their contribution to the preparation of publication on the results.

I am sincerely grateful to all my colleagues in the NIEH, who cooperated in the projects. I specially thank Dr. Erika Györfly, Katalin Kovács, Katalin Lévy, Gizella Istvánné Papp and Ágnes Gáborné Karácsonyi for all sorts of help and support.

I express my thanks to Dr. Szilárd Kostič, Dr. Attila Csekeő, Dr. Ibolya Soltész and Gabriella Fleischer (Korányi National Institute of Tuberculosis and Pulmonology, Budapest, Hungary), and to Dr. János Minárovits, Dr. Zoltán Györi and Dr. Judit Segesdi (National Center for Epidemiology, Budapest, Hungary) for the contribution in the sample collection.

The technical assistance by Tuula Suijala (FIOH, Helsinki) and Mayura Meerang (DKFZ, Heidelberg) is gratefully acknowledged.

This work was supported in parts by Environmental Cancer Risk, Nutrition and Individual Susceptibility (ECNIS), a Network of Excellence operating within the European Union 6th Framework Program, Priority 5: 'Food Quality and Safety' (Contract No 513943); the Országos Tudományos Kutatási Alap [OTKA T034616]; the Hungarian-Finnish Science and Technology Foundation [SF-02/01, SF-14/03]. I was awarded an ECNIS Exchange Fellowship to DKFZ, where I conducted the O<sup>4</sup>-ethylthymidine measurements.

I would like to thank my family and friends who always encouraged me, and who supported me with love and patience during the whole PhD process.